Dragonfly Therapeutics expands cancer deal with Celgene

15 November 2018

In a second deal within a matter of weeks, privately-held Cambridge, USA-based Dragonfly Therapeutics has entered into a new agreement with Celgene (Nasdaq: CELG) to discover, develop and commercialize innovative immunotherapies for patients with solid and hematological cancers.

The new agreement builds on Celgene's existing four-target collaboration with Dragonfly, agreed upon in 2017, and increases the number of TriNKET immunotherapy drug candidates available for in licensing by Celgene to a total of eight.

The original deal, announced in mid-2017, saw Dragonfly collect $33 million and covered up to four blood cancer drugs developed by the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK